Status:
COMPLETED
Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator
Lead Sponsor:
Chung Shan Medical University
Conditions:
Advanced Lung Cancer
Eligibility:
All Genders
20+ years
Brief Summary
The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs ...
Detailed Description
In recent years, the therapeutic strategies for lung cancer have been enriched with small molecular targeted therapy and immunotherapy. In this retrospective study, we will observe the change in NLR a...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Aged 20 years and older.
- Patients who have been given a diagnosis of lung cancer.
- Previously advanced lung cancer patients first treated with ICIs from Oct 1, 2015 to Oct 31, 2019.
- Exclusion Criteria
- Patients who have no hematological laboratory data available at baseline (within 3 days prior to ICI treatment) and the 6th week (± 2 weeks) after ICI treatment initiation.
Exclusion
Key Trial Info
Start Date :
April 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2020
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT04352335
Start Date
April 14 2020
End Date
July 1 2020
Last Update
July 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung Shan Medical University Hospital
Taichung, Taiwan